India's Pharma Exports are entering a new phase as drugmakers expand beyond their biggest market, the US, to tap fresh opportunities in Brazil.
Haryana has initiated a project under the Pharmaceuticals and Medical Devices Manufacturing Policy 2026, which attracts 10,000 crore in investment and 20,000 job opportunities, thereby making Haryana a unique state in coming up with likely projects
Medical Device Licences could soon become easier and quicker to obtain in India, a move that may do more than reduce paperwork.
Lupin secures a tentative approval from the USFDA further expanding India as the global leader in the pharmaceutical industry the drug actively blocks testosterone from stimulating cancer cell growth
Alembic Pharma has gained entry into the USD 27 million US flu drug market after receiving USFDA approval for its generic flu drug, Oseltamivir Phosphate for Oral Suspension.
India gets a rare end-to-end ADC manufacturing facility as Shilpa Biologicals, a material subsidiary of Shilpa Medicare, commissioned one of the country’s few fully integrated Antibody-Drug Conjugate (ADC) manufacturing plants.
India may be preparing for a major shift in its healthcare access as the government looks to accelerate medical devices manufacturing India and reduce the country's dependence on imported equipment.
Sun Pharma’s latest acquisition marks another strategic step in its efforts to strengthen its presence beyond traditional pharmaceuticals.
In an insightful discussion on “Building a Strong MedTech Ecosystem” with Thiruamuthan, Assistant Editor at India Pharma Outlook, Dr. Rajiv Chhibber, Joint Forum Coordinator, Association of Indian Medical Device Industry (AiMeD), shares his perspecti
Lupin enters hypertension drug market as it announced the commercial launch of Azilsartan Medoxomil tablets in the United States.
, CDSCO.jpg)